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Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers, with a median
survival of only three to six months. Standard treatment options and even targeted therapies have so far failed to
improve long-term overall survival. Thus, novel treatment modalities for ATC, such as immunotherapy, are
urgently needed. CD47 is a ‘‘don’t eat me’’ signal, which prevents cancer cells from phagocytosis by binding to
signal regulatory protein alpha on macrophages. So far, the role of macrophages and the CD47–signal regu-
latory protein alpha signaling axis in ATC is not well understood.
Methods: This study analyzed 19 primary human ATCs for macrophage markers, CD47 expression, and
immune checkpoints by immunohistochemistry. ATC cell lines and a fresh ATC sample were assessed by flow
cytometry for CD47 expression and macrophage infiltration, respectively. CD47 was blocked in phagocytosis
assays of co-cultured macrophages and ATC cell lines. Anti-CD47 antibody treatment was administered to
ATC cell line xenotransplanted immunocompromised mice, as well as to tamoxifen-induced ATC double-
transgenic mice.
Results: Human ATC samples were heavily infiltrated by CD68- and CD163-expressing tumor-associated
macrophages (TAMs), and expressed CD47 and calreticulin, the dominant pro-phagocytic molecule. In addi-
tion, ATC tissues expressed the immune checkpoint molecules programmed cell death 1 and programmed death
ligand 1. Blocking CD47 promoted the phagocytosis of ATC cell lines by macrophages in vitro. Anti-CD47
antibody treatment of ATC xenotransplanted mice increased the frequency of TAMs, enhanced the expres-
sion of macrophage activation markers, augmented tumor cell phagocytosis, and suppressed tumor growth.
In double-transgenic ATC mice, CD47 was expressed on tumor cells, and blocking CD47 increased TAM
frequencies.
Conclusions: Targeting CD47 or CD47 in combination with programmed cell death 1 may potentially improve
the outcomes of ATC patients and may represent a valuable addition to the current standard of care.
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Introduction
Anaplastic thyroid carcinoma (ATC) is one of themost aggressive solid tumors in humans, with a case
fatality rate approaching 100% and a median survival of
three to six months. With an incidence of one to two per
million people per year, ATC represents an orphan disease
that accounts for <10% of all thyroid cancers worldwide
(1,2). However, ATCs are most often locally advanced or
metastatic upon presentation and are therefore responsible
for a substantial fraction of thyroid cancer-related deaths
(3). Due to the rarity of this tumor, the management of
patients with ATC is based on clinical experience and
published case series. Depending on the disease stage and
local resectability, surgery combined with radiotherapy
and chemotherapy represents the current treatment of
choice. For inoperable and metastatic tumors, aggressive
therapy, consisting of tumor debulking surgery, before or
after local radiation and systemic therapy, or palliative care
are the only options (4). Radioactive iodine therapy is not
effective because ATCs do not concentrate iodine (5).
Survival rates have remained unchanged in the last 30 years.
Generally, regardless of treatment strategy, the outcomes of
ATC are very poor. Therefore, all ATC patients should be
considered candidates for clinical trials investigating novel
experimental approaches including targeted therapies and
immunotherapies (6,7).
Recently, therapies aiming at modulating the immune system
have led to impressive results in various advanced human tu-
mors (8). In particular, immune checkpoint inhibitors—ther-
apeutic antibodies that enhance antitumoral T-cell responses by
blocking inhibitory molecules such as cytotoxic T lymphocyte
antigen 4 (CTLA-4) and programmed cell death 1 (PD-1)—
have proven very effective and have even resulted in long-term
remission in patients with metastatic cancers (9,10). In addition,
accumulating evidence points toward a very important role for
innate immune cells, including natural killer (NK) cells and
tumor-associated macrophages (TAMs), in the biology of ma-
lignant neoplasms (11–13). TAMs are considered a double-
edged sword in cancer, showing either pro-tumorigenic or
tumor-suppressive functions depending on their activation state
(14). Because TAMs account for a major fraction of the immune
infiltrate in many tumors, reprogramming these cells toward an
antitumoral state by enhancing their capacity to phagocytose
tumor cell (‘‘programmed cell removal’’) is an attractive strat-
egy in cancer immunotherapy (15).
CD47 is an immunoglobulin family member protein
overexpressed on the surface of many cancer types, including
leukemias, lymphomas, and solid tumors (16–23). CD47 acts
as a ‘‘don’t eat me’’ signal by binding to signal regulatory
protein alpha (SIRPa) on macrophages and thereby inhibiting
phagocytosis of target cells (24–27). Consequently, CD47
blockade enhances tumor cell phagocytosis by TAMs, im-
proves survival in various murine cancer models, and is
currently being tested in multiple clinical trials (16,17,19–
22,28).
The present study investigated the role of TAMs and CD47
in ATC. It demonstrates that primary human ATCs are
heavily infiltrated by TAMs and express significant levels of
CD47 and calreticulin, the dominant pro-phagocytic mole-
cule (29), as well as the immune checkpoint molecules PD-1
and PD-1 ligand 1 (PD-L1). Blocking CD47 promoted the
phagocytosis of ATC cell lines by macrophages in vitro and
in vivo and increased the frequency of TAMs in ATC xeno-
grafts and in a double-transgenic ATC mouse model. Taken
together, these data reveal that targeting of CD47 may pro-
vide a novel therapeutic strategy for ATC patients for whom
effective therapeutic options are otherwise currently very
limited.
Methods
Patient samples
Formalin-fixed, paraffin-embedded (FFPE) tissues from
19 patients (14 females; Mage –SEM = 72.5– 2 years) with a
diagnosis of ATC between 2005 and 2018 were identified in
the archives of the Institute of Pathology, University of Bern
(Bern, Switzerland). Cases were reviewed in detail by three
board-certified surgical pathologists with a special interest in
thyroid pathology (A.P., A.M.S., and M.S.D.), and were
reclassified/restaged according to the 2017 World Health
Organization Classification of Tumors of Endocrine Organs
and the 2017 American Joint Committee on Cancer/Union for
International Cancer Control tumor-node-metastasis guide-
lines (30–32). Patient characteristics are detailed in Table 1
and Supplementary Table S1. The study was approved by the
local Ethics Committee of the Canton of Bern (KEK 200/14,
KEK 2018-01502). A fresh sample for fluorescence-activated
cell sorting (FACS) analysis was obtained after surgery and
diagnosis of ATC in frozen sections, with written informed
consent from the patient.
Immunohistochemistry
All sections were cut to 2 lm thickness. Hematoxylin and
eosin–stained sections were obtained from each FFPE block.
Immunohistochemistry (IHC) staining of full slides from
FFPE blocks was performed on a Leica BOND RX auto-
mated immunostainer using Bond primary antibody diluent
and Bond Polymer Refine DAB detection kit according to the
manufacturer’s instructions (Leica Biosystems). Details on
antibodies, clones, manufacturers, and staining conditions for
IHC are listed in Supplementary Table S2. Analysis and in-
terpretation of the staining results were performed by two
board-certified surgical pathologists (C.M.S and M.S.D.) and
one pathologist in training (S.F.) in accordance with the
‘‘REporting recommendations for tumor MARKer prognos-
tic studies’’ guidelines (33). Tumor cells were morphologi-
cally identified by cell size, shape, and nuclear configuration.
CD47 staining in tumor cells was classified microscopically
as 0 (absence of any membranous or cytoplasmic staining),
1+ (weak or incomplete membranous and/or cytoplasmic
staining), 2+ (complete membranous staining of intermediate
intensity), and 3+ (complete membranous staining of strong
intensity). The calreticulin staining pattern was mostly
granular and cytoplasmic and was classified microscopically
as 0–3+. For CD68, CD163, PD-1, and PD-L1 staining, the
positive cell frequencies were estimated by microscopy and
were quantified by QuPath analysis, as described below. The
concordance of microscopical estimation and QuPath quan-
tification was in the range of –10% for all cases, except for
PD-1 and PD-L1 staining in 7 and 10 cases, respectively,
which could not be evaluated adequately by automated Qu-
Path analysis due to the predominantly weak membranous
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staining pattern. Therefore, for PD-1 and PD-L1 staining,
only the values from microscopical estimation were used. All
results are detailed in Supplementary Table S1.
Slide digitization, cell annotation, and QuPath analysis
Slides were scanned using an Aperio Scanscope CS digital
slide scanner (Leica Biosystems) and analyzed using QuPath
software v0.1.2. (34). For each sample, a selected and defined
tumor area (at least 1 mm2) was analyzed. For detection of
macrophages (CD68, CD163), T cells (CD3, CD4, CD8),
granulocytes (CD15), NK cells (CD56), plasmacytoid den-
dritic cells (CD123), vasculature (CD31), as well as PD-1+
and PD-L1+ cells, the QuPath positive cell detection algo-
rithm was used with the following setup parameters: detec-
tion image, hematoxylin OD for CD68, CD163, PD-1, and
PD-L1; optical density sum for CD3, CD4, CD8, CD15,
CD56, CD123, and Ki-67; requested pixel size, 0.5 lm; nu-
cleus parameters—background radius 8 lm, median filter
radius 0 lm, sigma 2.0 lm, minimum area 10 lm2, and
maximum area 400lm2; intensity parameters—threshold
0.02, maximum background intensity 2.0, split by shape yes,
exclude DAB (membrane staining) no; cell parameters—cell
expansion 3lm include cell nucleus yes; general parame-
ters—smooth boundaries yes, make measurements yes; and
intensity threshold parameters—score compartment: cell,
DAB OD mean, threshold 1 + 0.2, single threshold yes. For
Ki-67 staining, the scoring compartment in intensity thresh-
old parameters was switched to nucleus: DAB OD mean. For
samples showing a stronger background staining (especially
CD163 IHC), setup intensity parameters were modified as
follows: intensity threshold parameters—score compart-
ment: cell, DAB OD mean, threshold 1 + 0.2, threshold
2 + 0.4, threshold 3 + 0.5, single threshold no. The quality of
segmentation and positive and negative cell detection was
visually analyzed and confirmed for each case.
Cell lines
The human ATC cell lines 8505C (35), 8305C (35), HTH-
104 (36), BHT-101 (37), CAL-62 (38), C643 (39), and
SW-1736 (40) were obtained from Prof. Dr. Martin Walter
(Department of Nuclear Medicine, Inselspital, Bern Uni-
versity Hospital, Bern, Switzerland), and have been de-
scribed before. The human ATC cell line OCUT-2 (41) was
obtained from R.-P.C. and has been described before.
Mice
NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ (NSG) mice (42) were
purchased from Charles River Laboratories. BrafCA/+; Pik3-
caLat/+; ThyroglobulinCreERT2 (Thyro-DT) mice from a
mixed FVB/C57BL6/F129 background have been previously
described (43). Mice were housed under specific pathogen-
free conditions in isolated ventilated cages on a 12-hour/12-
hour cycle of light and dark, fed ad libitum, and regularly
monitored for pathogens. All mouse experiments were li-
censed by the Canton of Bern and were performed in com-
pliance with Swiss Federal legislation.
In vitro phagocytosis assay
The in vitro phagocytosis assay was performed as de-
scribed before (23). Buffy coats and human serum were ob-
tained from the Swiss Blood Bank (Interregionale Blutspende
SRK, Bern, Switzerland) under the signed consent of the
donors and in agreement with local legislation. Peripheral
blood mononuclear cells (PBMCs) were enriched from buffy
coats by density centrifugation using Lympho Spin Medium
(pluriSelect). Monocytes were isolated from PBMCs using
the EasySep Human CD14 Positive Selection Kit II (Stemcell
Technologies) according to the manufacturer’s instructions.
Monocytes (4–5 · 106 per well) were differentiated into
Table 1. Patient Characteristics
Clinical characteristics at diagnosis
Age (mean –SEM), years 72.5– 2
Median, years 72
Range, years 58–86
Female/male ratio (n) 2.8 (14/5)
TNM classification and tumor staging, n
Primary tumor:
pT3a 3
pT4a 16
Regional lymph nodes:
pN0 2
pN1 9
pNX 8
Distant metastases:
M0 3
M1 11
MX 5
Resection status:
R0 1
R1/R2 13/5
Site of distant metastases:
Lung 6
Other 7
Unknown 4
AJCC stage:
IVB 7
IVC 12
Therapy, n
Thyroidectomy and/or tumor debulking 19
Neck dissection 9
Radiotherapy 8
Chemotherapy 5
Radioiodine therapy 1
Comfort/palliative therapy 7
Survival
Median (months) 3.5
Range (months) 0.9–61
<6 months, n 12
12–24 months, n 3
Alive with stable disease, n
(months after diagnosis)
1 (61)
Lost to follow-up, n
(months after diagnosis)
3 (1.9,
1.9, 18.1)
Cause of death, n
Tumor related 13
Non-tumor related 1
Unknown 1
Further details are listed in Supplementary Table S1.
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macrophages for seven days at 37C, 5% CO2, on six-well
tissue culture plates in Iscove’s Modified Dulbecco’s Med-
ium supplemented with 10% human serum, 1% L-glutamine,
and 1% penicillin/streptomycin. 8505C cells were harvested
using non-enzymatic cell dissociation buffer (Sigma–Aldrich),
washed in phosphate-buffered saline (PBS) three times, and
then labeled with 5(6)-carboxyfluorescein diacetate N-
succinimidyl ester (CFSE) in PBS at a final concentration of
20lM. Macrophages were starved in serum-free medium for
two hours, and 1· 106 CFSE-labeled 8505C cells per well were
added. Cells were co-cultured for two hours in the presence of
10lg/mL mouse anti-human CD47 (clone B6H12.2; Thermo
Fisher Scientific) or isotype control (mouse IgG1; Thermo
Fisher Scientific). Then, wells were imaged at 20·magnifi-
cation on a digital inverted fluorescence microscope (EVOS
FL imaging system; Thermo Fisher Scientific). Phase contrast
and green fluorescent protein (GFP) overlay images were ex-
ported, and the phagocytosis index and CFSE+ cells per mac-
rophage were manually determined by two pathologists in
training (S.F. and F.B.) in an independent fashion for each
experiment. After microscopic imaging, cells were harvested
using trypsin/EDTA solution (Sigma–Aldrich), stained for
anti-human CD45 and CD14, and analyzed by FACS.
Stable GFP transduction of 8505C cells
293T cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM)/F12 supplemented with 10% tetracycline-
free fetal calf serum (FCS), penicillin (100 IU/mL), and
streptomycin (100lg/mL), and grown to 80% confluency in
T150 flasks. The pLVX-EF1a-TS-EGFP-IRES-Puro vector
was cloned by introducing a TS-EGFP DNA string (GeneArt
Elements; Thermo Fisher Scientific) into the EcoRI and
BamHI sites of the pLVX-EF1a-IRES-Puro vector (Takara
Bio, Inc./Clontech). The construct was verified by sequencing.
For transient transfection of 293T cells, 20lg pLX-EF1a-TS-
EGFP-IRES-Puro and 60lL Lenti-X packaging mix (GE
Healthcare) were mixed with 240lL Dogtor (OZ Biosciences)
in a total volume of 500lL Opti-MEM (Thermo Fisher Sci-
entific) followed by 20 minutes of complex formation at room
temperature and incubation with the cells. Twenty-four hours
post transfection, the medium was exchanged. Lentiviral su-
pernatants were harvested at 48, 72, and 96 hours post trans-
fection and filtered through a 0.45lm PES filter, followed by
sixfold concentration with Lenti-X Concentrator (Takara
Bio, Inc./Clontech) according to the manufacturer’s in-
structions. 8505C cells cultured in T25 flasks in RPMI-1640
supplemented with 10% tetracycline-free FCS, penicillin/
streptomycin, and 1% L-glutamine were transduced three
times with 1 mL viral supernatant at a 1:5 dilution. Forty-eight
hours post transduction, cells were selected with puromycin at
a final concentration of 3lg/mL for nine days. Finally, GFPhi-
expressing cells were purified by FACS sorting.
Tumor cell injection, tumor measurement,
and treatment of NSG mice
Parental or stably GFPhi-expressing 8505C cells (4–5· 106)
were injected subcutaneously (s.c.) into the flanks of six-week-
old female NSG mice. Starting three days after tumor cell
injection, mice were treated with 500lg anti-human CD47
monoclonal antibody (mAb; clone B6H12; BioXCell) or
mouse IgG1 isotype control mAb (clone MOPC-21; BioX-
Cell) by intraperitoneal (i.p.) injection twice a week. Tumor
growth was measured with a caliper twice a week, and tumor
volumes were calculated by the formula V= (p·width·
length· height)/6. After five to six weeks, mice were sacrificed
by CO2 inhalation followed by cervical dislocation, and tu-
mors were excised, measured, and weighed.
Tumor induction, tumor measurement, and treatment
of Thyro-DT mice
Tumors were induced in Thyro-DT mice by daily i.p. in-
jections of 1 mg tamoxifen diluted in 100lL peanut oil
(Sigma–Aldrich) on five consecutive days. To monitor tumor
development, tumors were measured by ultrasound every
three weeks. Mice were anesthetized using 5lL/g of body
weight of a mixture of 0.1 mg/mL medetomidine, 0.5 mg/mL
midazolam, and 5 lg/mL fentanyl in 0.9% NaCl (Sigma–
Aldrich) by i.p. injection. The fur around the neck was epi-
lated with Veet hair removal cream. Images were acquired
with an ESAOTE MyLab Five ultrasound device equipped
with an 18 MHz LA455 Probe (Siemens). After imaging,
anesthesia was reversed with 10 lL/g body weight of a
mixture of 0.25 mg/mL atipamezole, 5 lg/mL flumazenil,
and 20lg/mL naloxone in 0.9% NaCl (Sigma–Aldrich) by
s.c. injection. Ultrasound images were analyzed using ImageJ
software. After three months of tumor growth, tumor-bearing
mice were evenly divided into two groups according to tumor
sizes. All mice weighed between 20 and 30 g at the start of the
experiment. Mice were treated with either 500lg (5 mg/mL)
of anti-mouse/human/rat CD47 mAb (clone MIAP410;
BioXCell; treatment group) or 100ll InVivoPure, pH 7.0,
dilution buffer (BioXCell; control group) by i.p. injection
twice a week. During treatment, ultrasound measurements of
tumor size were performed every two weeks. Tumor size was
approximated by the biggest area in cross-section found for
each tumor. Continuous measurements were normalized to
the measurement at the start of treatment to create tumor
growth curves for each individual mouse.
Perfusion and organ excision
For sample preparation, Thyro-DT mice were anesthetized
with 10 mg/mL ketamine and 1.6 mg/mL xylazine at a dose of
10lL/g body weight by i.p. injection. When mice were
unresponsive to mechanical stimuli, the thoracic and abdom-
inal cavities were opened. The heart was punctured on the right
side, and PBS supplemented with 137 mM NaCl, 2.7 mM KCl,
18 mM KH2PO4, and 100 mM Na2HPO4 (Sigma–Aldrich) at
room temperature was injected to the left side of the heart for
perfusion. Successful perfusion was confirmed by liver deco-
loration. Organs were excised and stored in ice-cold DMEM
supplemented with 10% FCS, penicillin/streptomycin, 2 mM
L-glutamine, and 1% MEM non-essential amino acids solution
(Thermo Fisher Scientific).
Tumor and thyroid dissociation
The fresh human ATC sample, subcutaneous tumors of
NSG mice, and thyroids of Thyro-DT mice were washed with
PBS, cut into small pieces, and enzymatically digested on a
shaker for 60 minutes at 37C in 5 mL RPMI-1640 supple-
mented with 1 mL 0.25% trypsin and 1 ml (0.1 g/mL) colla-
genase IV (Sigma–Aldrich). After digestion, supernatants
were filtered through 70lm cell strainers and washed with
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RPMI-1640, and cells were disaggregated by slowly pushing
cell suspensions through 20G followed by 24G needles. Then,
cells were washed, filtered through 40lm cell strainers, and re-
suspended in RPMI-1640 supplemented with 10% FCS.
Flow cytometry (FACS)
ATC cell lines were cultured to 70% confluence and har-
vested using non-enzymatic cell dissociation buffer (Sigma–
Aldrich). All stainings were performed in PBS for 20–30
minutes at 4C. Details on antibodies, clones, manufacturers,
and staining conditions for FACS are listed in Supplementary
Table S3. Fixable Viability Dye-eFluor506 (dilution 1:4000)
was from eBioscience. For mouse thyroid tumors, stained
cells were washed and fixed using the BD Cytoperm/Cytofix
kit (BD Biosciences) according to the manufacturer’s in-
structions. Samples were acquired on a BD LSR II flow
cytometer (Becton Dickinson) and were analysed using
FlowJo software (TreeStar). Samples from NSG mice in-
jected with GFPhi-expressing 8505C cells were also acquired
on an ImageStreamX Mark II imaging flow cytometer and
analyzed using IDEAS software (Amnis/EMD Millipore).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
v5.0 (GraphPad Software). Data are represented as the
mean – standard error of the mean.
FIG. 1. Human anaplastic
thyroid carcinomas (ATCs)
express phagocytosis signal-
ing and immune checkpoint
molecules and are heavily
infiltrated by macrophages.
Hematoxylin and eosin
(H&E) staining and immu-
nohistochemistry (IHC) for
CD47, calreticulin (CALR),
macrophage markers (CD68
and CD163), and checkpoint
molecules (PD-1 and PD-L1)
in ATCs. (A and B) Patient
#8: epithelioid and sarcoma-
toid variant of ATC. CD47:
2+; CALR: 3+; CD68: 40%
positive cells; CD163: 29%
positive cells; PD-1: 5%
positive cells; PD-L1: 70%
positive cells. (C and D)
Patient #14: epithelioid vari-
ant of ATC. CD47: 1+;
CALR: 2+; CD68: 14% pos-
itive cells; CD163: 28%
positive cells; PD-1: 10%
positive cells; PD-L1: 70%
positive cells. (E) IHC
staining intensity of CD47
and CALR in ATCs, as ana-
lyzed by semi-quantitative
microscopy. (F) Percentages
of CD68+ cells and CD163+
cells in ATCs, as analyzed by
automated quantification
(QuPath). (G) Percentages of
PD-1+ cells and PD-L1+ cells
in all tumors, as analyzed by
microscopy. Scale bars:
40 lm.
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Results
Human ATCs express CD47 and are heavily infiltrated
by macrophages
To study the role of CD47 and TAMs in ATC, FFPE tis-
sues were used from a retrospective cohort of 19 patients
who underwent surgery at the authors’ hospital from 2005 to
2018. In this cohort, the median survival was 3.5 months
(range 0.9–61 months). Patients were treated by either sur-
gery alone or a combination of surgery, radiotherapy, and/or
chemotherapy, as well as palliative supportive care (Table 1,
Supplementary Table S1, and Supplementary Fig. S1). IHC
revealed that most ATCs expressed low to moderate levels of
CD47 in a cytoplasmic and/or membranous staining pattern
(Fig. 1A, C, and E). Flow cytometry (FACS) analysis of a
dissociated fresh ATC indicated strong surface CD47 ex-
pression in the CD45- cell fraction containing the tumor cells
(Supplementary Fig. S2). The pro-phagocytic molecule
calreticulin was moderately to strongly expressed in a dot-
like cytoplasmic pattern in most tumors analyzed by IHC
(Fig. 1A, C, and E).
Previous studies have shown that ATCs are heavily in-
filtrated by TAMs (44–46). IHC was therefore performed
for the macrophage markers CD68 and CD163 on the dif-
ferent ATC cases, which showed a mean macrophage in-
filtration rate of 17% (CD68) and 23% (CD163), as analyzed
by automated digital quantification (Fig. 1B, D, and F and
Supplementary Fig. S3). Similar results were obtained by
FACS analysis of the dissociated fresh ATC tumor, with
13.5% of total cells being positive for CD68 (Supplemen-
tary Fig. S2). CD68 and CD163 percentages correlated
moderately with each other; strong correlation was observed
between automated quantification and semi-quantitative
microscopic analysis for each macrophage marker (Sup-
plementary Fig. S4).
Furthermore, PD-1 was expressed in ATCs on tumor cells,
as well as on cells showing the histomorphological features of
macrophages. Moreover, in line with previous studies (47–
49), many tumors expressed high levels of the PD-1 ligand 1
(PD-L1; Fig. 1B, D, and G).
To address possible histological differences in patients
with longer compared to shorter survival, the cohort was
split into two groups: those surviving <6 vs. >12 months
( p < 0.01). Tumor cell mitoses, CD68+ or CD163+ macro-
phages, CD47, calreticulin, or checkpoint molecules were
not significantly different in these two groups (Supple-
mentary Fig. S5). Furthermore, in-depth IHC analyses of the
three most extreme outliers were performed (shortest- vs.
longest-surviving patients with survival of <2 vs. >18
months, respectively). These results showed a trend toward
higher percentages of T cells, lower tumor cell mitoses, and
lower infiltration of CD15+ granulocytes and CD163+
macrophages in longer-surviving patients (Supplementary
Fig. S6).
In summary, these data indicate that ATCs express the
dominant pro-phagocytic molecule calreticulin, as well as the
‘‘don’t eat me’’ signal CD47 and the immune checkpoint
molecules PD-1 and PD-L1, all of which are currently tar-
geted therapeutically in other types of cancer. In addition,
they confirm that ATCs are infiltrated by innate and adaptive
immune cells, pointing toward an important role of the im-
mune microenvironment in these tumors.
Blocking CD47 promotes the phagocytosis of human
ATC cell lines by macrophages
To investigate the effects of blocking anti-CD47 mAbs on
phagocytosis of human ATC cell lines by macrophages
in vitro, first the expression of CD47 and calreticulin was
analyzed by FACS and IHC. Both CD47 and calreticulin
were significantly expressed on the surface of all eight ATC
cell lines analyzed (Fig. 2A–C). In addition to membranous
staining, IHC revealed weak cytoplasmic CD47 staining in
most cell lines (Fig. 2C). Next, human macrophages were co-
cultured with CFSE-labeled 8505C ATC cells in the presence
of anti-CD47 or isotype control mAb. Inverted fluorescence
microscopy of co-cultures (Fig. 2D) revealed that blocking
CD47 significantly increased the numbers of macrophages
with phagocytosed ATC cells (phagocytosis index, Fig. 2E),
as well as the number of phagocytosed ATC cells per mac-
rophage (Fig. 2F). These results were further validated by
FACS analysis of the co-cultures (Fig. 2G and H). Thus,
blocking CD47 promotes the phagocytosis of human ATC
cells by macrophages.
‰
FIG. 2. CD47 blockade promotes macrophage-mediated phagocytosis of human ATC cells. (A) Expression of CD47 and
calreticulin on the ATC cell lines 8505C and OCUT-2, respectively, as analyzed by fluorescence-activated cell sorting
(FACS). One representative histogram of three to four per staining is shown. Red lines, CD47 and calreticulin staining,
respectively; blue lines, corresponding isotype controls. (B) Mean fluorescence intensity (MFI) of CD47 versus isotype (left
panel) and calreticulin versus isotype (right panel) in eight different ATC cell lines. Pooled data from four independent
experiments are shown. (C) IHC staining for CD47 on formalin-fixed, paraffin-embedded (FFPE) cell blocks from ATC cell
lines. Scale bars: 50 lm. (D–H) In vitro phagocytosis assay. Peripheral blood mononuclear cell–derived macrophages were
serum starved for two hours, followed by co-culture with 1· 106 5(6)-carboxyfluorescein diacetate N-succinimidyl ester
(CFSE)-labeled 8505C cells in the presence of 10 lg/mL IgG isotype control or anti-CD47 monoclonal antibody (mAb). (D)
After two hours of co-culture, wells were thoroughly washed, and multiple fields of view (FOV) were imaged on an inverted
fluorescence microscope. (D) Representative overlay images (one section of a FOV) for each condition are shown. Scale
bars: 400lm. (E) The percentage of macrophages with ingested CFSE+ tumor cells (phagocytosis index) and (F) the
number of ingested tumor cells per macrophage were determined. Each dot represents a FOV (IgG: n= 3605 macrophages
from 10 FOV; anti-CD47: n= 3371 macrophages from 11 FOV). One representative of two independent experiments is
shown. (G and H) After microscopy, cells were dissociated, stained, and analyzed by FACS. (G) Gating strategy and (H)
percentages of CFSE+ CD45+ CD14+ macrophages. Each dot represents one individual well of a six-well plate. One
representative out of three independent experiments (each with two to three wells per condition) is shown. Statistics: (B)
paired t-test, (E, F, and H) Student’s t-test. *p< 0.05; **p < 0.01; ****p < 0.0001.
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FIG. 3. CD47 blockade increases tumor-associated macrophage (TAM) frequency, promotes phagocytosis, and inhibits
ATC growth in vivo. (A–H) 8505C cells (5· 106) were injected subcutaneously (s.c.) into each flank of NSG mice. After three
days, mice were treated with 500lg anti-CD47 mAb (n= 5) or IgG isotype control mAb (n= 5) intraperitoneally (i.p.) twice a
week for six weeks and (A) tumor volumes were monitored using a caliper at the indicated time points after injection.
(B) Tumor weights and (C) representative images of tumors at the endpoint. Scale bar: 1 cm. (D–H) Tumors were dissociated
and analyzed by FACS. (D and E) The frequencies of tumor-infiltrating (D) total CD45+ cells and (E) CD11b+ F4/80+
macrophages as well as the MFIs of (F) CD11b and (G) F4/80 expression on CD11b+ F4/80+ macrophages were determined.
(H) MFI of CD47 staining versus isotype control on CD45- tumor cells of IgG- and anti-CD47-treated mice. CD47 staining
was performed using the same mAb clone as for treatment. (I–O) Stably GFP-expressing 8505C cells (4· 106) were injected
s.c. into each flank of NSG mice. After three days, mice were treated with 500lg anti-CD47 mAb (n= 4) or IgG isotype
control mAb (n= 4) i.p. twice a week. Five weeks later, tumors were excised, and (I) tumor volumes and (J) tumor weights
were measured. (K) The frequency of CD11b+ F4/80+ macrophages and (L) MFI of CD47 staining versus isotype control on
CD11b- tumor cells. (M) The MFI of PD-1 expression on CD11b+ F4/80+ macrophages as well as (N) the frequency of GFP+
CD11b+ F4/80+ macrophages were determined. (O) ImageStream analysis of GFP+ CD11b+ F4/80+ macrophages from IgG-
and anti-CD47-treated mice. One representative image of n= 25 (anti-CD47) and n= 10 (IgG) cells from two tumors per
treatment group is shown. Scale bars: 10lm. (P) Correlation of tumor weights and the frequencies of tumor-infiltrating
CD11b+ F4/80+ macrophages in both experiments. Exp1, data from (A–H); exp2, data from (I–O). Statistics: (A) two-way
analysis of variance, (B and D–N) Student’s t-test, (P) two-tailed t-test. *p< 0.05; **p< 0.01; ***p< 0.001; ****p< 0.0001.
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Blocking CD47 inhibits ATC growth and increases
TAMs and tumor cell phagocytosis in vivo
To validate the in vitro phagocytosis assays in vivo, xe-
notransplantation studies were performed by injecting 8505C
cells subcutaneously into the flanks of NOD.Cg-Prkdcscid
Il2rgtm1WjI/SzJ (NSG) mice. After three days of engraftment,
mice were treated with blocking anti-human CD47 mAb or
IgG isotype control twice a week. Blocking CD47 resulted in
significantly reduced tumor volumes and weights after six
weeks of treatment (Fig. 3A–C). Frequencies of CD45+
tumor-infiltrating leukocytes and CD11b+ F4/80+ double-
positive (DP) macrophages were significantly higher in anti-
CD47-treated mice (Fig. 3D and E). Interestingly, the
expression of CD11b integrin and F4/80 was also signifi-
cantly increased in TAMs from anti-CD47-treated mice
compared to controls (Fig. 3F and G), suggesting that
blocking CD47 activates macrophage function. Importantly,
the lack of signal on CD45- tumor cells upon CD47 staining
using the same mAb clone as for treatment indicated that the
CD47 blockade was effective in vivo (Fig. 3H).
To investigate in more detail whether anti-CD47 treatment
indeed improves phagocytosis by the accumulated TAMs,
stably GFP-expressing 8505C cells were xenotransplanted into
NSG mice. Tumor volumes and weights (Fig. 3I and J), the
frequency of DP macrophages in tumors (Fig. 3K), and the
blocking of CD47 on GFP-expressing 8505C cells (Fig. 3L)
were comparable to conditions using parental 8505C cells.
Interestingly, a higher PD-1 expression was observed on DP
macrophages from anti-CD47-treated mice (Fig. 3M). More
importantly, the frequency of GFP-expressing DP macro-
phages was significantly higher in anti-CD47-treated mice
compared to controls, as analyzed by FACS (Fig. 3N). This
was confirmed by ImageStream analysis showing GFP+
cellular debris inside DP macrophages (Fig. 3O). In addition,
tumor weights in both experiments inversely correlated with
the frequency of DP macrophages in tumors (Fig. 3P), indi-
cating that tumor weight and volume in xenotransplanted mice
were substantially affected by the presence of infiltrating
macrophages.
In summary, these results indicate that anti-CD47 treat-
ment promotes the accumulation of activated TAMs and
improves their phagocytic function in ATC tumors in vivo.
Blocking CD47 increases TAMs in a transgenic ATC
mouse model
To study the effects of anti-CD47 treatment in a more
clinically relevant setting, we made use of the BrafCA/+;
Pik3caLat/+; ThyroglobulinCreERT2 (Thyro-DT) mouse
model (43). Thyro-DT mice start developing fatal high-grade
thyroid carcinomas between three and six months after
transgene induction with tamoxifen. First, the expression of
CD47 and macrophage markers was analyzed in FFPE thy-
roid tissues from tumor-bearing Thyro-DT mice. Neoplastic
epithelial cells showed intermediate to strong expression of
CD47 (Fig. 4A). Staining for CD68 and F4/80 revealed nu-
merous TAMs in the neoplastic epithelium and tumor stroma
(Fig. 4A). Three months after tamoxifen induction, tumor-
bearing mice were divided into two groups with similar tu-
mor sizes, as measured by ultrasound. Mice were treated with
either anti-CD47 mAb or antibody dilution buffer, respec-
tively, and subsequent tumor growth was repeatedly mea-
sured by ultrasound. During the 10-week treatment period,
mouse tumors nearly doubled in size. Yet, no significant
difference in tumor size was observed between the two
groups (data not shown). However, FACS analysis of spleens
revealed that anti-CD47 treatment had induced significantly
increased frequencies of CD8+ T cells and a trend toward
higher frequencies of DP macrophages. Proportions of sple-
nic CD4+ T cells remained comparable between the two
experimental groups (Fig. 4B–D). Interestingly, the expres-
sion of CD80 on DP macrophages in the spleen was signifi-
cantly increased after CD47 blockade (Fig. 4E). In thyroids,
there was a trend toward higher frequencies of total tumor-
infiltrating CD45+ cells, and the frequency of CD11b+ mac-
rophages was significantly increased (Fig. 4F and G). FACS
analysis using anti-mouse immunoglobulin revealed that the
therapeutic CD47 mAb had effectively bound on the surface
of CD45- EpCAM+ tumor cells (data not shown).
These data indicate that murine ATCs are infiltrated by
macrophages in vivo and suggest that CD47 blockade mod-
ulates the composition of the tumor immune infiltrate as well
as systemic immunity in transgenic ATC-bearing mice.
Discussion
ATC is a rare, aggressive tumor for which effective
therapeutic options are limited. Many ATCs harbor one or
multiple recurrent genetic mutations that are potentially
druggable (50). Targeted therapy approaches that have been
reported or are currently being tested clinically, alone or in
combination with chemotherapy, include BRAF inhibitors
(51), BRAF/MEK inhibitors (Clinicaltrials.gov identifier
NCT02034110) (52), mechanistic target of rapamycin
(mTOR) inhibitors (NCT02244463, NCT00936858) (53),
improved multi-kinase inhibitors (54), novel anti-microtubule
agents (55), peroxisome proliferator-activated receptor-c
(PPAR-c) agonists (56), combined histone deacetylase
(HDAC) and phosphoinositide 3-kinase (PI3K) inhibitors
(NCT03002623), and anaplastic lymphoma kinase (ALK)
inhibitors (57). However, most of these small-molecule
therapies only work in subgroups of ATCs with the respective
driver mutations or pathway alterations. In addition, the plas-
ticity of cancer cells in general often rapidly leads to therapy-
induced drug resistance under single-agent small molecule
treatments by mechanisms such as drug target mutation or al-
ternative activation of the targeted pathways (58). Therefore,
such treatments usually fail to induce long-lasting remissions.
In contrast to the above-mentioned mutations, most of
which are only present in subgroups of ATC (50), most ATC
tumors are infiltrated by TAMs and T cells and express
CD47 and PD-L1 (44–47,49). Moreover, compared to
small molecule inhibitors, immunotherapy—particularly
the blockade of PD-1, PD-L1, or CTLA-4—is inherently
multivalent because a single drug unleashes multi-specific
antitumoral T-cell responses (59). Resistance mechanisms
to immunotherapy have also been observed and are related
to diverse factors, including the tumor microenvironment,
patient age, hormonal levels, and the microbiome (60).
Nevertheless, immune checkpoint inhibitors have shown
exceptional efficacy and have led to long-lasting remissions
in subgroups of patients harboring a broad array of advanced
and even metastatic solid tumors, as well as hematological
cancers (61,62).
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For ATC, clinical immunotherapy trials that investigate
immune checkpoint inhibitory mAbs against PD-1 (NCT
02721732, NCT02404441) or a combination of anti-CTLA-4
+ anti-PD-1 mAbs (NCT03246958) are currently under way.
In addition to checkpoint inhibitors that mainly act by in-
creasing the function of effector T cells (59), recent research
activities have focused on antitumoral mediators of the in-
nate immune system, mainly NK cells and macrophages
(15,63,64). Hitherto, TAMs have generally been labeled as a
pro-tumorigenic cell population. M2-polarized TAMs pro-
duce cytokines and chemokines that directly promote tumor
growth, induce angiogenesis and tumor cell invasion, and
suppress effective adaptive immune responses against tumors
(65,66). Concordantly, in the present cohort, patients with
long survival (i.e., >12 months, including a patient who is still
alive 61 months after diagnosis) generally showed lower
numbers of TAMs that express the scavenger receptor
CD163, a marker for M2 macrophages (Supplementary
Fig. S5) (67). Attempts to eliminate TAMs using mAbs
against colony stimulating factor 1 (CSF-1) or small mole-
cule inhibitors targeting the c-fms tyrosine kinase of its re-
ceptor (CSF-1R/CD115) have proven effective in various
murine cancer models and are investigated in numerous
clinical trials (68,69).
On the other hand, instead of removing M2-polarized TAMs
from tumors, reprogramming them toward an antitumoral,
FIG. 4. CD47 blockade
promotes TAM accumulation
in a transgenic mouse model
of ATC. (A) H&E staining
and IHC for CD47, CD68,
and F4/80 in FFPE tumor
samples from Thyro-DT
mice. One representative
image of tumors from eight
mice is shown for each
staining. Scale bars: 200 lm.
(B–G) Three months after
transgene induction, tumor-
bearing Thyro-DT mice were
divided in two groups with
similar tumor size and
treated with either 500lg
anti-CD47 mAb (n = 4) or
antibody dilution buffer
(n = 5) by i.p. injection twice
a week. Tumor growth was
measured by ultrasound ev-
ery two weeks and normal-
ized to baseline before start
of treatment. After 10 weeks
of treatment, mice were sac-
rificed, and spleens and thy-
roids were analyzed by
FACS. (B–D) Frequencies of
(B) CD4+ T cells, (C) CD8+
T cells, and (D) CD11b+ F4/
80+ macrophages were de-
termined in the spleen. (E)
MFI of CD80 expression on
splenic CD11b+ F4/80+
macrophages. (F and G) The
frequencies of tumor-
infiltrating (F) total CD45+
cells and (G) CD11b+ macro-
phages were determined in the
thyroids of Thyro-DT mice.
Data from one thyroid lobe
per mouse are shown. Statis-
tics: Student’s t-test. *p<0.05.
n.s., not significant.
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inflammatory M1 (classical) phenotype is an attractive
therapeutic strategy (66). Classically activated TAMs
stimulated by bacterial products (70) or anti-CD40 mAbs
(71) effectively inhibit tumor growth. Because TAMs form a
substantial fraction of total cells in most ATCs, we hy-
pothesize that their activation against tumor cells represents
a powerful strategy. We found that CD47 blockade in vivo
induced an upregulation of CD11b, F4/80, and CD80 on
TAMs and splenic macrophages, respectively, which is
consistent with macrophage activation. Moreover, in ATC
xenotransplanted NSG mice, anti-CD47 mAb treatment in-
creased TAM frequencies and promoted phagocytosis of
tumor cells, resulting in significantly delayed tumor growth.
Correspondingly, blocking CD47 increased TAM frequen-
cies in transgenic Thyro-DT mice compared to controls.
However, in this model, differences in tumor growth were
not observed. Furthermore, in ATC xenotransplanted NSG
mice, CD47 blockade increased PD-1 expression in TAMs.
Besides the well-established role for PD-1 in the suppression
of adaptive antitumoral T-cell responses (9), it was shown
that TAMs express PD-1, which inhibits their phagocytosis
and thereby also prevents innate antitumoral immunity (72).
Therefore, future studies should address co-inhibition of
CD47/SIRPa and PD-1/PD-L1 in ATC. This combination
will likely further enhance TAM activity and tumor cell
phagocytosis and induce synergistic antitumoral CD8+ T-
cell responses (47,49). Concordantly, Liu et al. recently
demonstrated that treatment with a bispecific anti-PD-L1/
SIRPa mAb induced effective, combined adaptive and in-
nate antitumoral immune responses against PD-L1- and
CD47-expressing solid tumors, including colorectal cancer
and melanoma (73).
In summary, our work provides evidence that the ‘‘don’t
eat me’’ signal CD47 is expressed on human ATC to prevent
TAM-mediated tumor phagocytosis. Our findings also sug-
gest that anti-CD47 alone or combined with anti-PD-1 mAb
immunotherapies may represent a valuable addition to the
current standard of care for ATC patients.
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